drugset / Trial / NCT06760039

Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCL

NCT06760039

Phase 1/2 Recruiting 112 enrolled Sun Yat-sen University
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a prospective, randomized, controlled, multicenter, phase II clinical trial to evaluate the efficacy and safety of R-CMOP versus R-CHOP in the initial treatment of low-risk and medium-risk diffuse large B-cell lymphoma (DLBCL).

Timeline

Start
2025-01-10
Primary completion
2028-08-31
Completion
2028-11-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Doxorubicinin Unknown Intravenous
Subject Mitoxantrone Small molecule Intravenous
Background Cyclophosphamide Other / unclassified Intravenous
Background Prednisone Other / unclassified Oral
Background Rituximab Monoclonal antibody Intravenous
Background Vincristine Small molecule Intravenous